Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral COVID-19 Hospital.
Antibody
COVID-19
IgA
IgG
SARS-CoV-2
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
27
10
2020
accepted:
17
04
2021
pubmed:
11
5
2021
medline:
17
2
2022
entrez:
10
5
2021
Statut:
ppublish
Résumé
Antibody response plays a fundamental role in the natural history of infectious disease. A better understanding of the immune response in patients with SARS-CoV-2 infection could be important for identifying patients at greater risk of developing a more severe form of disease and with a worse prognosis. We performed a cross-sectional analysis to determine the presence and the levels of both anti-SARS-CoV-2 IgG and IgA in a cohort of hospitalized patients with confirmed infection at different times in the natural history of the disease. Patients enrolled when admitted at the emergency department were prospectively followed up during hospital stay. Overall, 131 patients were considered with a total of 237 samples processed. Cross-sectional analysis showed that seroconversion for IgA seems to occur between days 6 and 15, while IgG response seems to occur slightly later, peaking at day 20 after symptoms onset. Both IgA and IgG were maintained beyond 2 months. Severe patients showed a higher IgA response compared with mild patients when analyzing optical density (8.3 versus 5.6, p < 0.001). Prospective analysis conducted on 55 patients confirmed that IgA appear slightly earlier than IgG. After stratifying for the severity of disease, both the IgA and IgG responses were more vigorous in severe cases. Moreover, while IgG tended to stabilize, there was a relevant decline after the first month of IgA levels in mild cases. IgA and IgG antibody response is closely related, although seroconversion for IgA occurs earlier. Both IgA and IgG are maintained beyond 2 months. Severe patients showed a more vigorous IgA and IgG response. IgA levels seem to decline after 1 month since the onset of symptoms in mild cases. Our results should be interpreted with cautions due to several limitations in our study, mainly the small number of cases, lack of data on viral load and clinical setting.
Identifiants
pubmed: 33970428
doi: 10.1007/s11739-021-02750-8
pii: 10.1007/s11739-021-02750-8
pmc: PMC8107418
doi:
Substances chimiques
Immunoglobulin A
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-64Informations de copyright
© 2021. Società Italiana di Medicina Interna (SIMI).
Références
Zhu N, Zhang D, Wang W et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733. https://doi.org/10.1056/NEJMoa2001017
doi: 10.1056/NEJMoa2001017
pubmed: 31978945
pmcid: 7092803
Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 395:565–574. https://doi.org/10.1016/S0140-6736(20)30251-8
doi: 10.1016/S0140-6736(20)30251-8
WHO (2020) WHO Director-General’s opening remarks at the media briefing on COVID-19—11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 . Accessed 15 May 2020
WHO https://covid19.who.int/
Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA 323:1239. https://doi.org/10.1001/jama.2020.2648
doi: 10.1001/jama.2020.2648
pubmed: 32091533
Li Z, Yi Y, Luo X et al (2020) Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 92:1518–1524. https://doi.org/10.1002/jmv.25727
doi: 10.1002/jmv.25727
pubmed: 32104917
Deeks JJ, Dinnes J, Takwoingi Y et al (2020) Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane database Syst Rev 6:CD013652. https://doi.org/10.1002/14651858.CD013652
doi: 10.1002/14651858.CD013652
pubmed: 32584464
Lee N, Chan PKS, Ip M et al (2006) Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J Clin Virol 35:179–184. https://doi.org/10.1016/j.jcv.2005.07.005
doi: 10.1016/j.jcv.2005.07.005
pubmed: 16112612
Ip M, Chan PKS, Lee N et al (2004) Seroprevalence of antibody to severe acute respiratory syndrome (SARS)-associated coronavirus among health care workers in SARS and non-SARS medical wards. Clin Infect Dis 38:e116–e118. https://doi.org/10.1086/421019
doi: 10.1086/421019
pubmed: 15227633
Lee HKK, Tso EYK, Chau TN et al (2003) Asymptomatic severe acute respiratory syndrome–associated coronavirus infection. Emerg Infect Dis 9:1491–1492. https://doi.org/10.3201/eid0911.030401
doi: 10.3201/eid0911.030401
pubmed: 14725258
pmcid: 3035549
Tso EYK, Tsang OTY, Lam B et al (2004) Natural course of severe acute respiratory syndrome-associated coronavirus immunoglobulin after infection. J Infect Dis 190:1706–1707. https://doi.org/10.1086/424573
doi: 10.1086/424573
pubmed: 15478079
Wilder-Smith A, Teleman MD, Heng BH et al (2005) Asymptomatic SARS coronavirus infection among healthcare workers, Singapore. Emerg Infect Dis 11:1142–1145. https://doi.org/10.3201/eid1107.041165
doi: 10.3201/eid1107.041165
pubmed: 16022801
pmcid: 3371799
Hsueh P-R, Huang L-M, Chen P-J et al (2004) Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect 10:1062–1066. https://doi.org/10.1111/j.1469-0691.2004.01009.x
doi: 10.1111/j.1469-0691.2004.01009.x
pubmed: 15606632
Li G, Chen X, Xu A (2003) Profile of specific antibodies to the SARS-associated coronavirus. N Engl J Med 349:508–509. https://doi.org/10.1056/NEJM200307313490520
doi: 10.1056/NEJM200307313490520
pubmed: 12890855
He Z, Dong Q, Zhuang H et al (2004) Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS. Clin Diagnostic Lab Immunol 11:792–794. https://doi.org/10.1128/CDLI.11.4.792-794.2004
doi: 10.1128/CDLI.11.4.792-794.2004
Haveri A, Smura T, Kuivanen S et al (2020) Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Eurosurveillance. https://doi.org/10.2807/1560-7917.ES.2020.25.11.2000266
doi: 10.2807/1560-7917.ES.2020.25.11.2000266
pubmed: 32209163
pmcid: 7678039
Okba NMA, Müller MA, Li W et al (2020) Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease patients. Emerg Infect Dis 26:1478–1488. https://doi.org/10.3201/eid2607.200841
doi: 10.3201/eid2607.200841
pubmed: 32267220
pmcid: 7323511
Zhao J, Yuan Q, Wang H et al (2020) Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa344
doi: 10.1093/cid/ciaa344
pubmed: 33367582
pmcid: 8664468
Di Giambenedetto S, Ciccullo A, Posteraro B et al (2020) Still much to learn about the diagnostic role of SARS-CoV-2 antibody detection. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa532
doi: 10.1093/cid/ciaa532
pubmed: 32358955
pmcid: 7583402
Wu F, Wang A, Liu M et al (2020) Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. https://doi.org/10.1101/2020.03.30.20047365
doi: 10.1101/2020.03.30.20047365
pubmed: 33330880
pmcid: 7743089
Terauchi Y, Sano K, Ainai A et al (2018) IgA polymerization contributes to efficient virus neutralization on human upper respiratory mucosa after intranasal inactivated influenza vaccine administration. Hum Vaccin Immunother 14:1351–1361. https://doi.org/10.1080/21645515.2018.1438791
doi: 10.1080/21645515.2018.1438791
pubmed: 29425074
pmcid: 6037454
Woo PCY, Lau SKP, Wong BHL et al (2004) Longitudinal profile of immunoglobulin G (IgG), IgM, and IgA antibodies against the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein in patients with pneumonia due to the SARS coronavirus. Clin Diagn Lab Immunol 11:665–668. https://doi.org/10.1128/CDLI.11.4.665-668.2004
doi: 10.1128/CDLI.11.4.665-668.2004
pubmed: 15242938
pmcid: 440610
Lippi G, Mattiuzzi C (2020) Clinical value anti-SARS-COV-2 serum IgA titration in patients with COVID-19. J Med Virol. https://doi.org/10.1002/jmv.26539
doi: 10.1002/jmv.26539
pubmed: 33295648
pmcid: 7537252
Xue M, Zhang T, Hu H et al (2020) Predictive effects of IgA and IgG combination to assess pulmonary exudation progression in COVID-19 patients. J Med Virol. https://doi.org/10.1002/jmv.26437
doi: 10.1002/jmv.26437
pubmed: 33174624
pmcid: 7461178
Chao YX, Rötzschke O, Tan E-K (2020) The role of IgA in COVID-19. Brain Behav Immun 87:182–183. https://doi.org/10.1016/j.bbi.2020.05.057
doi: 10.1016/j.bbi.2020.05.057
pubmed: 32454136
pmcid: 7245198
Bernard GR, Artigas A, Brigham KL et al (1994) The American-European Consensus on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818–824. https://doi.org/10.1164/ajrccm.149.3.7509706
doi: 10.1164/ajrccm.149.3.7509706
pubmed: 7509706
Definition Task Force ARDS, Ranieri VM, Rubenfeld GD et al (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307:2526–2533. https://doi.org/10.1001/jama.2012.5669
doi: 10.1001/jama.2012.5669
World Medical Association (2013) World Medical Association Declaration of Helsinki. JAMA 310:2191. https://doi.org/10.1001/jama.2013.281053
doi: 10.1001/jama.2013.281053
Cleveland WS (1979) Robust locally weighted regression and smoothing scatterplots. J Am Stat Assoc 74:829. https://doi.org/10.2307/2286407
doi: 10.2307/2286407
R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
RStudio Team (2019) RStudio: Integrated Development Environment for R. R. RStudio Inc, Boston
Wickham H, Averick M, Bryan J et al (2019) Welcome to the Tidyverse. J Open Source Softw 4:1686. https://doi.org/10.21105/joss.01686
doi: 10.21105/joss.01686
Gudbjartsson DF, Norddahl GL, Melsted P et al (2020) Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med. https://doi.org/10.1056/NEJMoa2026116
doi: 10.1056/NEJMoa2026116
pubmed: 33147384
pmcid: 7494247
Long Q-X, Liu B-Z, Deng H-J et al (2020) Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 26:845–848. https://doi.org/10.1038/s41591-020-0897-1
doi: 10.1038/s41591-020-0897-1
pubmed: 32350462
Huang Z, Chen H, Xue M et al (2020) Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19. Clin Exp Immunol. https://doi.org/10.1111/cei.13500
doi: 10.1111/cei.13500
pubmed: 33270222
pmcid: 7405228
Hasan Ali O, Bomze D, Risch L et al (2020) Severe COVID-19 is associated with elevated serum IgA and antiphospholipid IgA-antibodies. Clin Infect Dis. https://doi.org/10.1093/cid/ciaa1496
doi: 10.1093/cid/ciaa1496
Yu H-Q, Sun B-Q, Fang Z-F et al (2020) Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J 56:7–10. https://doi.org/10.1183/13993003.01526-2020
doi: 10.1183/13993003.01526-2020
Tay MZ, Poh CM, Rénia L et al (2020) The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20:363–374. https://doi.org/10.1038/s41577-020-0311-8
doi: 10.1038/s41577-020-0311-8
pubmed: 32346093
Jose RJ, Manuel A (2020) COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 8:e46–e47. https://doi.org/10.1016/S2213-2600(20)30216-2
doi: 10.1016/S2213-2600(20)30216-2
pubmed: 32353251
Mehta P, McAuley DF, Brown M et al (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0
doi: 10.1016/S0140-6736(20)30628-0
García LF (2020) Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front Immunol 11:1441. https://doi.org/10.3389/fimmu.2020.01441
doi: 10.3389/fimmu.2020.01441
pubmed: 32612615
pmcid: 7308593
Yang W, Sirajuddin A, Zhang X et al (2020) The role of imaging in 2019 novel coronavirus pneumonia (COVID-19). Eur Radiol. https://doi.org/10.1007/s00330-020-06827-4
doi: 10.1007/s00330-020-06827-4
pubmed: 33219848
pmcid: 7722255
Ma H, Zeng W, He H et al (2020) Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol 17:773–775. https://doi.org/10.1038/s41423-020-0474-z
doi: 10.1038/s41423-020-0474-z
pubmed: 32467617
pmcid: 7331804
Zhu Z, Cai T, Fan L et al (2020) Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis 95:332–339. https://doi.org/10.1016/j.ijid.2020.04.041
doi: 10.1016/j.ijid.2020.04.041
pubmed: 32334118
pmcid: 7195003
Sinha P, Matthay MA, Calfee CS (2020) Is a “cytokine storm” relevant to COVID-19? JAMA Intern Med 180:1152. https://doi.org/10.1001/jamainternmed.2020.3313
doi: 10.1001/jamainternmed.2020.3313
pubmed: 32602883
Lucas C, Wong P, Klein J et al (2020) Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 584:463–469. https://doi.org/10.1038/s41586-020-2588-y
doi: 10.1038/s41586-020-2588-y
pubmed: 32717743
pmcid: 7477538
Zhang Q, Bastard P, Liu Z et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370:eabd4570. https://doi.org/10.1126/science.abd4570
doi: 10.1126/science.abd4570
pubmed: 32972995
pmcid: 7857407
Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. https://doi.org/10.1126/science.abd4585
doi: 10.1126/science.abd4585
pubmed: 32972996
pmcid: 7857407
Moore JB, June CH (2020) Cytokine release syndrome in severe COVID-19. Science 368:473–474. https://doi.org/10.1126/science.abb8925
doi: 10.1126/science.abb8925
pubmed: 32303591
Fajgenbaum DC, June CH (2020) Cytokine Storm. N Engl J Med 383:2255–2273. https://doi.org/10.1056/NEJMra2026131
doi: 10.1056/NEJMra2026131
pubmed: 33264547
pmcid: 7727315